Ahmad Masri, Mark V Sherrid, Theodore P Abraham, Lubna Choudhury, Pablo Garcia-Pavia, Christopher M Kramer, Roberto Barriales-Villa, Anjali T Owens, Florian Rader, Sherif F Nagueh, Iacopo Olivotto, Sara Saberi, Albree Tower-Rader, Timothy C Wong, Caroline J Coats, Hugh Watkins, Michael A Fifer, Scott D Solomon, Stephen B Heitner, Daniel L Jacoby, Stuart Kupfer, Fady I Malik, Lisa Meng, Regina L Sohn, Amy Wohltman, Martin S Maron
BACKGROUND: This open-label phase 2 trial evaluated the safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). METHODS: Patients with symptomatic nHCM (left ventricular outflow tract obstruction gradient ≤30 mmHg, left ventricular ejection fraction [LVEF] ≥60%, N-terminal pro-B-type natriuretic peptide [NT-proBNP] >300 pg/mL) received aficamten 5-20 mg once daily (doses adjusted according to echocardiographic LVEF) for 10 weeks...
March 15, 2024: Journal of Cardiac Failure